Amplera Biosciences is a molecular diagnostics technology company. We develop the technologies behind molecular tests, and we help others turn those technologies into products that perform in the clinic, the field and the market.
Molecular biology has never produced more promising diagnostic ideas. Far fewer become products that a laboratory can trust, a manufacturer can make, and a regulator can approve.
A method that performs on a good day — with a skilled hand and a clean sample — still has to survive difficult matrices, variable operators, shipping and storage, lot-to-lot variation, and the scrutiny of a regulatory file. Most promising assays stall in that distance, between a result in a paper and a result every day, everywhere.
Between discovery, engineering, validation, manufacturing and regulation — each handled by a different group, none accountable for the whole. Amplera was built to hold all of it under a single responsibility.
A brilliant result is a beginning. A diagnostic that works every time, in the conditions where it will actually be used, is the achievement.
We work toward a future in which a reliable molecular answer is available wherever a decision depends on it — not only in a reference laboratory, but in a hospital, a clinic, a veterinary practice, an aquaculture facility, a food or water testing site, and a public health program in the field.
Health is not confined to human medicine, and neither is our vision. As pathogens move between people, animals and the environment, dependable diagnostics must move with them. We are building toward a One Health future in which the same rigor that protects a patient also protects a herd, a harvest and a water supply.
Targets are selected on genomic evidence and designed with computational biology before a reaction is ever run. Assays are engineered — not merely designed — for sensitivity, specificity and stability under real conditions. Performance is established through analytical validation against criteria defined before the study starts, and quality is built in from the first experiment through Quality by Design rather than inspected at the end.
We hold a strict line between what a test can do analytically and how it performs clinically, and we state only what the evidence supports.
Every assay is developed with its eventual setting in mind — the sample it will see, the hands that will run it, and the conditions it must withstand.
Claims are earned through data, performance is stated with the conditions that make it meaningful, and uncertainty is acknowledged rather than obscured. Within that discipline, four things shape how we work.
We are a technology company before we are a service provider. The platforms we develop for our own research are the ones we bring to your program, so you build on capability we own rather than on generic protocols. What we build for you stays yours.
We develop diagnostics as products, not experiments. Reproducibility across operators, instruments and lots, manufacturability and stability are settled in the first design, so a validated assay is also a viable one.
Quality is a decision made at the beginning, not a check performed at the end. Evidence and documentation are structured as the work proceeds, not reconstructed before submission.
Because we develop across human, animal, environmental and food and water health, we bring scientific context a single-domain provider cannot.
Amplera is led by a founder-scientist team with backgrounds in molecular diagnostics, CRISPR biology and regulatory affairs, supported by advisors in bioinformatics, clinical validation and quality systems. Every program is assigned one named scientific lead, accountable from requirements through transfer.
To close the distance between a working method and a dependable product.
With internal amplification control, transferred to the client with SOPs, QC release criteria and the full validation report.
Our guide design engine, developed into a multiplexed CRISPR detection chassis.
Uniting isothermal amplification, CRISPR detection and lateral flow into one validated, point-of-care chassis.
Tell us the target and the sample type. We will come back within one business day with a feasibility view, a likely development path and an indicative timeline.